Deirdre R Pachman1, Rui Qin2, Drew K Seisler2, Ellen M L Smith2, Andreas S Beutler2, Lauren E Ta2, Jacqueline M Lafky2, Nina D Wagner-Johnston2, Kathryn J Ruddy2, Shaker Dakhil2, Nathan P Staff2, Axel Grothey2, Charles L Loprinzi2. 1. Deirdre R. Pachman, Rui Qin, Drew K. Seisler, Andreas S. Beutler, Lauren E. Ta, Jacqueline M. Lafky, Kathryn J. Ruddy, Nathan P. Staff, Axel Grothey, and Charles L. Loprinzi, Mayo Clinic, Rochester, MN; Ellen M.L. Smith, University of Michigan, Ann Arbor, MI; Nina D. Wagner-Johnston, Washington University School of Medicine, Saint Louis, MO; and Shaker Dakhil, Cancer Center of Kansas, Wichita, KS. pachman.deirdre@mayo.edu. 2. Deirdre R. Pachman, Rui Qin, Drew K. Seisler, Andreas S. Beutler, Lauren E. Ta, Jacqueline M. Lafky, Kathryn J. Ruddy, Nathan P. Staff, Axel Grothey, and Charles L. Loprinzi, Mayo Clinic, Rochester, MN; Ellen M.L. Smith, University of Michigan, Ann Arbor, MI; Nina D. Wagner-Johnston, Washington University School of Medicine, Saint Louis, MO; and Shaker Dakhil, Cancer Center of Kansas, Wichita, KS.
Abstract
PURPOSE: Given that the clinical course of oxaliplatin-induced neuropathy is not well defined, the current study was performed to better understand clinical parameters associated with its presentation. METHODS:Acute and chronic neuropathy was evaluated in patients receiving adjuvant FOLFOX (fluorouracil, leucovorin, and oxaliplatin) on study N08CB (North Central Cancer Treatment Group, Alliance). Acute neuropathy was assessed by having patients complete daily questionnaires for 6 days with each cycle of FOLFOX. Before each dose of FOLFOX and as long as 18 months after chemotherapy cessation, chronic neurotoxicity was assessed with use of the 20-item, European Organisation for Research and Treatment of Cancer quality-of-life questionnaire for patients with chemotherapy-induced peripheral neuropathy. RESULTS: Three hundred eight (89%) of the 346 patients had at least one symptom of acute neuropathy with the first cycle of FOLFOX; these symptoms included sensitivity to touching cold items (71%), sensitivity to swallowing cold items (71%), throat discomfort (63%), or muscle cramps (42%). Acute symptoms peaked at day 3 and improved, although they did not always resolve completely between treatments. These symptoms were about twice as severe in cycles 2 through 12 as they were in cycle 1. For chronic neurotoxicity, tingling was the most severe symptom, followed by numbness and then pain. During chemotherapy, symptoms in the hands were more prominent than they were in the feet; by 18 months, symptoms were more severe in the feet than they were in the hands. Patients with more severe acute neuropathy during the first cycle of therapy experienced more chronic sensory neurotoxicity (P < .0001). CONCLUSION: Acute oxaliplatin-induced neuropathy symptoms do not always completely resolve between treatment cycles and are only half as severe on the first cycle as compared with subsequent cycles. There is a correlation between the severities of acute and chronic neuropathies.
RCT Entities:
PURPOSE: Given that the clinical course of oxaliplatin-induced neuropathy is not well defined, the current study was performed to better understand clinical parameters associated with its presentation. METHODS: Acute and chronic neuropathy was evaluated in patients receiving adjuvant FOLFOX (fluorouracil, leucovorin, and oxaliplatin) on study N08CB (North Central Cancer Treatment Group, Alliance). Acute neuropathy was assessed by having patients complete daily questionnaires for 6 days with each cycle of FOLFOX. Before each dose of FOLFOX and as long as 18 months after chemotherapy cessation, chronic neurotoxicity was assessed with use of the 20-item, European Organisation for Research and Treatment of Cancer quality-of-life questionnaire for patients with chemotherapy-induced peripheral neuropathy. RESULTS: Three hundred eight (89%) of the 346 patients had at least one symptom of acute neuropathy with the first cycle of FOLFOX; these symptoms included sensitivity to touching cold items (71%), sensitivity to swallowing cold items (71%), throat discomfort (63%), or muscle cramps (42%). Acute symptoms peaked at day 3 and improved, although they did not always resolve completely between treatments. These symptoms were about twice as severe in cycles 2 through 12 as they were in cycle 1. For chronic neurotoxicity, tingling was the most severe symptom, followed by numbness and then pain. During chemotherapy, symptoms in the hands were more prominent than they were in the feet; by 18 months, symptoms were more severe in the feet than they were in the hands. Patients with more severe acute neuropathy during the first cycle of therapy experienced more chronic sensory neurotoxicity (P < .0001). CONCLUSION: Acute oxaliplatin-induced neuropathy symptoms do not always completely resolve between treatment cycles and are only half as severe on the first cycle as compared with subsequent cycles. There is a correlation between the severities of acute and chronic neuropathies.
Authors: A G E M de Boer; J J B van Lanschot; P F M Stalmeier; J W van Sandick; J B F Hulscher; J C J M de Haes; M A G Sprangers Journal: Qual Life Res Date: 2004-03 Impact factor: 4.147
Authors: T J Postma; N K Aaronson; J J Heimans; M J Muller; J G Hildebrand; J Y Delattre; K Hoang-Xuan; M Lantéri-Minet; R Grant; R Huddart; C Moynihan; J Maher; R Lucey Journal: Eur J Cancer Date: 2005-04-14 Impact factor: 9.162
Authors: Stephanie R Land; Jacek A Kopec; Reena S Cecchini; Patricia A Ganz; H Samuel Wieand; Linda H Colangelo; Kate Murphy; J Philip Kuebler; Thomas E Seay; Burton M Needles; James D Bearden; Lauren K Colman; Keith S Lanier; Eduardo R Pajon; David Cella; Roy E Smith; Michael J O'Connell; Joseph P Costantino; Norman Wolmark Journal: J Clin Oncol Date: 2007-04-30 Impact factor: 44.544
Authors: Dona E C Locke; Paul A Decker; Jeff A Sloan; Paul D Brown; James F Malec; Matthew M Clark; Teresa A Rummans; Karla V Ballman; Paul L Schaefer; Jan C Buckner Journal: J Pain Symptom Manage Date: 2007-08-20 Impact factor: 3.612
Authors: Gregory D Leonard; Maurice A Wright; Mary G Quinn; Suzanne Fioravanti; Nancy Harold; Barbara Schuler; Rebecca R Thomas; Jean L Grem Journal: BMC Cancer Date: 2005-09-16 Impact factor: 4.430
Authors: Hannah C Timmins; Tiffany Li; Terry Trinh; Matthew C Kiernan; Michelle Harrison; Frances Boyle; Michael Friedlander; David Goldstein; Susanna B Park Journal: Oncologist Date: 2021-02-10
Authors: A Sobrero; A Grothey; T Iveson; R Labianca; T Yoshino; J Taieb; T Maughan; M Buyse; T André; J Meyerhardt; A F Shields; I Souglakos; J-Y Douillard; A Cervantes Journal: Ann Oncol Date: 2018-05-01 Impact factor: 32.976
Authors: Timothy Iveson; Kathleen A Boyd; Rachel S Kerr; Jose Robles-Zurita; Mark P Saunders; Andrew H Briggs; Jim Cassidy; Niels Henrik Hollander; Josep Tabernero; Andrew Haydon; Bengt Glimelius; Andrea Harkin; Karen Allan; John McQueen; Sarah Pearson; Ashita Waterston; Louise Medley; Charles Wilson; Richard Ellis; Sharadah Essapen; Amandeep S Dhadda; Mark Harrison; Stephen Falk; Sherif Raouf; Charlotte Rees; Rene K Olesen; David Propper; John Bridgewater; Ashraf Azzabi; David Farrugia; Andrew Webb; David Cunningham; Tamas Hickish; Andrew Weaver; Simon Gollins; Harpreet Wasan; James Paul Journal: Health Technol Assess Date: 2019-12 Impact factor: 4.014
Authors: Grace A Kanzawa-Lee; Robert Knoerl; Clare Donohoe; Celia M Bridges; Ellen M Lavoie Smith Journal: Semin Oncol Nurs Date: 2019-04-30 Impact factor: 2.315